A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Sponsor: GlaxoSmithKline
This PHASE2 trial investigates Anaemia and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Aichi, Japan , Alcalá de Henares, Spain , Amiens, France , Anyang-Si Gyeonggi-do, South Korea , Azusa, United States , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Bethlehem, United States and 101 more locations